CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-11-11 | Semerjian Harout Chief Executive Officer | Purchase | +25,000 | $1.29 | $32K | 25,000 |
| 2022-11-11 | Hahn Brian M. SVP Finance, CFO | Purchase | +20,000 | $1.06 | $21K | 56,843 |
| 2022-11-11 | Magnani John L. SVP of Research, CSO | Purchase | +45,045 | $1.17 | $53K | 366,078 |
| 2022-11-11 | Girard Armand SVP, Chief Business Officer | Purchase | +6,500 | $1.05 | $7K | 29,161 |
| 2022-09-02 | Rock Edwin Chief Medical Officer | Grant or award · Employee stock option (right to buy) | +200,000 | 200,000 | ||
| 2022-05-18 | PEARSON TIMOTHY R Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | Koenig Scott Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | King Rachel K. Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | JUNIUS DANIEL M Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | Jackson Scott Thomas Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | Goldberg Mark Alan Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-05-18 | Andrews Patricia S Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 | ||
| 2022-03-09 | Magnani John L. SVP of Research, CSO | Sale | −3,227 | $1.09 | $4K | 321,033 |
| 2022-03-09 | Girard Armand SVP, Chief Business Officer | Sale | −2,339 | $1.09 | $3K | 22,661 |
| 2022-03-09 | Hahn Brian M. SVP Finance, CFO | Sale | −2,917 | $1.09 | $3K | 36,843 |
| 2022-01-21 | Girard Armand SVP, Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +144,700 | 144,700 | ||
| 2022-01-21 | Girard Armand SVP, Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +47,700 | 47,700 | ||
| 2022-01-21 | Magnani John L. SVP of Research, CSO | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2022-01-21 | Magnani John L. SVP of Research, CSO | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2022-01-21 | Hahn Brian M. SVP Finance, CFO | Grant or award · Employee Stock Option (right to buy) | +164,700 | 164,700 |
Page 8 of 16 · 305 trades